1. The Use of Autologous Falciform Ligament as a Vascular Graft. (2021) Authors: Wu, G.; Boue, A.; Fagan, P.; Johnston, P.; Meyer-Rochow, W.; Bartlett, A. Journal: HPB Issue: Volume 23(2021)Supplement 1 Page Start: S432 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Non-clinical identification and characterization of KRAS G12D inhibitors. (October 2022) Authors: Brooun, A.; Bae, J.H.; Chen, H.; Li, P.; Lin, B.; Fagan, P.; Irimia, A.; Nevarez, R.; Zhang, J.; Chen, P.; Olaharski, D.; Chiang, G.; Vernier, J.M.; Shoemaker, R. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Entrectinib, a highly potent pan-Trk, ROS1, and ALK inhibitor, has broad-spectrum, histology-agnostic anti-tumor activity in molecularly defined cancers. (December 2016) Authors: Wei, G.; Patel, R.; Walsh, C.; Barrera, M.; Fagan, P.; Murphy, D.; Christiansen, J.; Shoemaker, R.; Hornby, Z.; Li, G.G. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S33 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗